Skip to content
★ Sign in to follow
Lumibird logo

Lumibird Stock: price and insider trades · France

ISIN FR0000038242FR·Mcap €495.4MTechnology

No insider purchase over the last 90 days. The latest, by LUMIBIRD SA, was filed 07 Aug 2026.

Lumibird: what insiders have been doing

This page follows insider dealings at Lumibird as filed with AMF, a company from the Technology sector based in Lannion, France. The group dates from 1970. 1 insider has disclosed 1 filing since 10 November 2025.

The flow runs one way only: 1 sale worth €249k, from 1 insider, and no purchase. One trade stands out by size: a sale of €249k from Lumibird SA, disclosed on 31 July 2026, or 0.048% of market capitalisation.

Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification.

Across the 316 companies tracked on its exchange, the median is 6 filings; at 1 filing, this issuer sits below that mark. Since 2023, the database holds no purchases and 2 sales by insiders of the company.

Other companies in the same sector with recent insider buying flagged by our signals: Core Scientific, Inc./tx and Gitlab Inc. Every figure here comes from the filings published by AMF and describes the past, not future prices; it is not investment advice.

Key facts

Headquarters: Lannion, France · Founded: 1970

Source: Wikidata (CC0).

Insider Decl.
2
Thresholds
n/a
Buy Volume
n/a
n/a
Sell Volume
€977,989
2 ops. · all time

Who traded when

BuySale
Lumibird SA1 buy1 sale
Fundamental score
Ranked 14,254 of 26,911 companies
49.8
score / 100
Value
44
Quality
56
FCF yld2.3%
Earn yld2.6%
EV/EBITDA15.7x
ROE7.0%
Gross mgn64%
Net mgn6.1%
Debt/EBITDA3.3x
Pillars2/3

Transparent value + quality ranking, distinct from the insider signal.

Financial data

as of FY 2025

FY ended December 2025 · cache

€22.45
Analyst consensus
3 analysts
1.00/5
€30.00Target €31.83(+42%)€34.00
Income statement
Revenue€228.5M
Gross profit€146.2M64% margin
EBITDA€44.3M19% margin
Net income€14.0M6.0% margin
Valuation
PER (trailing)35.1x
PER (forward)17.1x
P/Book2.4x
Beta0.99
Balance sheet & cash
Market cap€495.4M
Total debt€146.2M
Free Cash Flow€12.6M
Debt / Equity73%
Profitability & ownership
ROE7.0%
ROA3.6%
% insiders53.6%
% institutions17.7%
Last declaration on 31 July 2026
Declarations2 total
  • ▼
    Related company / holdingExecutives
    €249k39AMF
    9,154 shares@ €27.200.048% mcap100.0% of flowActionEuronext ParisISIN FR00000382422026DD1130666
  • ▼
    Related company / holdingExecutives
    €729k15AMF
    50,000 shares@ €14.58100.0% of flowActionEuronext ParisISIN FR00000382422023DD918405

2 of 2 declarations

About Lumibird

Lumibird is a French specialist in laser technologies and one of Europe’s leading laser groups. Listed on Euronext under the ticker LBIRD and identified by ISIN FR0000038242, the company designs, manufactures and markets laser systems and related subsystems for three main end markets: scientific research, industrial applications and medical uses. Its offering is built on three core laser technologies: solid-state lasers, laser diodes and fiber lasers. The group is particularly well positioned in ophthalmology, as well as in defense, LiDAR sensing and high-precision measurement applications.

The group’s roots date back to 1997, when Marc Le Flohic founded Optocom Innovation, the company that later became Keopsys. Lumibird first expanded through organic development, before accelerating its growth via acquisitions and mergers from 2014 onward. A defining milestone came in October 2017, when Keopsys and Quantel merged to create Lumibird, establishing a European laser champion. The group then broadened its portfolio and geographic reach through acquisitions including Optotek Medical in 2019, Halo Photonics in 2019, Ellex Medical in 2020 and Convergent in 2023.

Read moreShow less

Operationally, Lumibird is organized around two complementary divisions. The Photonics division serves scientific, industrial and defense markets with high-performance laser sources, rangefinders, sensors and electro-optical systems. The Medical division brings together the Quantel Medical, Ellex and Optotek Medical brands, offering diagnostic and therapeutic laser solutions for ophthalmology. This structure gives the group a balanced exposure to different demand drivers, combining innovation-intensive niche markets with recurring medical applications and defense-related opportunities.

Lumibird operates an integrated industrial model, supported by research, manufacturing and sales capabilities across 14 countries. The company states that it employs around 1,000 people, with 12 R&D sites, 10 production sites and 15 commercial subsidiaries. Its historical base remains in Lannion, Brittany, but its industrial footprint and customer base are international. In 2025, the group reported annual revenue of €225.6 million, up 8.9% as reported and 10.2% at constant scope and exchange rates, confirming solid momentum across both divisions.

A noteworthy feature of Lumibird is its positioning in highly technical, innovation-driven markets where technological depth and industrial reliability are critical competitive advantages. The group has also highlighted defense-related contract wins in 2025 and 2026, underscoring the increasing strategic importance of this segment within its revenue mix. Overall, Lumibird combines a strong French industrial heritage, a global commercial footprint and a differentiated expertise in laser technologies.